• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    Chinese Journal of Stroke

    Chinese Journal of Stroke

    JournalISSN 1673-5765

    年发文量

    研究主题

    论文(4557)

    排序
    1俯卧位通气联合康复训练对重症卒中后气管切开合并坠积性肺炎患者的疗效观察Efficacy of Prone Position Ventilation Combined with Rehabilitation Training in Severe Post-Stroke Patients with Tracheostomy and Hypostatic Pneumonia
    FAN Xiangde

    目的 观察俯卧位通气(prone position ventilation,PPV)联合康复训练对重症卒中后气管切开合并坠积性肺炎患者的疗效。 方法 前瞻性连续纳入2023年9月—2025年4月在中国康复研究中心(北京博爱医院)重症医学科和重症康复科住院的重症卒中后气管切开合并坠积性肺炎患者,采用分层区组随机化方法,按1∶1的比例将患者分为试验组和对照组。两组均在临床标准化治疗基础上进行常规康复训练,试验组在此基础上加用PPV,每日1次,每次90 min,每周5 d,持续2周。采用比例优势模型(主分析)比较两组的临床疗效,进一步校正年龄、入组时NIHSS评分与卒中类型行多因素分析(敏感性分析),并比较干预前后的痰液性质、氧合指数、动脉血二氧化碳分压(arterial partial pressure of carbon dioxide,PaCO2)、白细胞计数(white blood cell count,WBC)和降钙素原(procalcitonin,PCT)水平。 结果 共纳入62例患者,试验组和对照组各31例。患者平均年龄(58±10)岁,男性49例(79.0%),女性13例(21.0%)。干预2周后,试验组显效15例、有效14例、无效2例,对照组显效6例、有效17例、 无效8例,试验组临床疗效优于对照组(共同OR 4.20,95%CI 1.54~12.33,P=0.006;多因素校正后OR 4.45,95%CI 1.53~12.93,P=0.006)。两组治疗后的痰液性质差异有统计学意义(P=0.010)。经基线校正后,氧合指数的均数差(试验组-对照组)为38.4 mmHg(1 mmHg=0.133 kPa)(95%CI 14.1~62.6 mmHg,P=0.002);PaCO2的均数差为-4.33 mmHg(-6.92~-1.73 mmHg,P=0.002);WBC的均数差为-1.83×109/L(-2.66×109/L~-1.00×109/L,P<0.001);PCT的均数差为-0.27 μg/L(-0.37~-0.17 μg/L,P<0.001);PCT经对数尺度分析的几何均值比为0.44(0.27~0.73,P=0.002)。 结论 在临床标准化治疗基础上,PPV联合康复训练可有效改善重症卒中后气管切开合并坠积性肺炎患者的临床疗效,更好地促进痰液性质、血气分析和炎症指标的改善。 Objective To observe the efficacy of prone position ventilation (PPV) combined with rehabilitation training in severe post-stroke patients with tracheostomy and hypostatic pneumonia. Methods Severe post-stroke patients who had a tracheostomy and hypostatic pneumonia and were hospitalized in the Intensive Care Unit and Department of Critical Care Rehabilitation at China Rehabilitation Research Center (Beijing Boai Hospital) from September 2023 to April 2025 were prospectively and consecutively enrolled. Patients were randomized at a 1∶1 ratio into the experimental group and the control group using stratified block randomization. Both groups received routine rehabilitation training in addition to standardized clinical treatment, while the experimental group underwent PPV once daily for 90 minutes per session, 5 days per week, for 2 weeks. The clinical efficacy of the two groups was evaluated using a proportional odds model. Multivariate analysis was performed with adjustment for age, NIHSS score at baseline, and stroke type. Sputum characteristics, oxygenation index, arterial partial pressure of carbon dioxide (PaCO2), white blood cell count (WBC), and procalcitonin (PCT) levels before and after the intervention were compared between the two groups. Results A total of 62 patients were enrolled, with 31 in each group. The mean age of patients was (58±10) years; 49 (79.0%) were male and 13 (21.0%) were female. After 2 weeks of intervention, 15 patients in the experimental group showed marked effectiveness, 14 showed effectiveness, and 2 showed ineffectiveness; in the control group, 6 showed marked effectiveness, 17 showed effectiveness, and 8 showed ineffectiveness. The clinical efficacy of the experimental group was superior to that of the control group (common OR 4.20, 95%CI 1.54-12.33, P=0.006; after multivariable adjustment, OR 4.45, 95%CI 1.53-12.93, P=0.006). The difference in sputum characteristics after treatment between the two groups was statistically significant (P=0.010). The baseline-adjusted mean differences (experimental group minus control group) were as follows: oxygenation index 38.4 mmHg (1 mmHg=0.133 kPa) (95%CI 14.1-62.6 mmHg, P=0.002); PaCO₂ −4.33 mmHg (95%CI −6.92-−1.73 mmHg, P=0.002); WBC −1.83×10⁹/L (95%CI −2.66×10⁹/L-−1.00×10⁹/L, P<0.001); PCT −0.27 μg/L (95%CI −0.37-−0.17 μg/L, P<0.001). The geometric mean ratio for PCT on the log scale was 0.44 (95%CI 0.27-0.73, P=0.002). Conclusions On the basis of standardized clinical treatment, PPV combined with rehabilitation training can effectively improve clinical outcomes in severe post-stroke patients who have a tracheostomy and hypostatic pneumonia, and can further improve sputum characteristics, blood gas parameters, and inflammatory markers.

    2026
    引用
    AI阅读
    加入学术空间
    2重症卒中机械通气患者肺与膈肌双重保护策略Dual Lung- and Diaphragm-Protective Ventilation Strategies in Mechanically Ventilated Patients with Severe Stroke
    FU Yanxin

    重症卒中患者的机械通气管理同时受到脑灌注、肺应力和膈肌负荷的制约。过度依赖控制通气可加速膈肌失用,而过早恢复或维持过强的自主呼吸又可能增大跨肺压及加剧颅内压波动。本文聚焦有创机械通气阶段,梳理脑-肺-膈交互损伤、脑保护约束下的肺保护边界、呼吸驱动与膈肌活动监测,以及撤机评估的相关证据,提出“脑危象期优先维持稳定、平衡期恢复适度呼吸努力、撤机期兼顾气道保护”的分期管理路径。现有监测阈值多源于一般重症人群,尚需卒中特异性研究进一步验证。 Mechanical ventilation management in patients with severe stroke is constrained simultaneously by cerebral perfusion, pulmonary stress and diaphragmatic load. Over-reliance on controlled ventilation accelerates diaphragm disuse atrophy, whereas restoring or maintaining excessive spontaneous effort too early may increase transpulmonary pressure and provoke fluctuations in intracranial pressure. Focusing on the period of invasive mechanical ventilation, this review summarises current evidence on brain-lung-diaphragm cross-talk, the boundaries of lung-protective ventilation under brain-protective constraints, the monitoring of respiratory drive and diaphragmatic activity, and weaning assessment. On this basis, a staged management pathway is proposed: prioritising intracranial and haemodynamic stability during the brain-crisis phase, restoring moderate and synchronous respiratory effort during the balance phase, and weighing ventilatory capacity together with airway protection during the weaning phase. Most currently available monitoring thresholds are derived from general critically ill populations and require validation in stroke-specific studies.

    2026
    引用
    AI阅读
    加入学术空间
    3重症卒中患者肠内营养相关性腹泻风险预测模型的构建及验证Development and Validation of a Risk Prediction Model for Enteral Nutrition-Associated Diarrhea in Severe Stroke Patients
    SHU Jun

    目的 分析重症卒中患者发生肠内营养相关性腹泻(enteral nutrition-associated diarrhea,ENAD)的危险因素,构建并验证其风险预测模型。 方法 回顾性连续纳入2023年8月1日—2025年11月30日首都医科大学附属北京天坛医院急诊抢救室收治的接受肠内营养的重症卒中患者,按6∶4的比例随机分为训练集与验证集。采用最小绝对值收缩与选择算子(least absolute shrinkage and selection operator,LASSO)回归筛选变量,并运用多因素logistic回归构建预测模型。采用ROC的AUC、校准曲线、决策曲线分析评估模型的区分度、校准度和临床净获益。 结果 本研究共纳入1206例重症卒中患者,ENAD发生率为30.6%(369/1206)。训练集结果显示,有冠心病病史(OR 2.22,95%CI 1.26~3.92,P=0.006)、使用轻泻药(OR 2.35,95%CI 1.58~3.48,P<0.001)与ENAD风险增加显著相关,而较高的白蛋白水平则与ENAD风险降低显著相关(OR 0.34,95%CI 0.23~0.52,P<0.001)。模型在训练集中的AUC为0.777(95%CI 0.742~0.812),敏感度为0.75(0.70~0.81),特异度为0.68(0.63~0.72);在验证集中的AUC为0.774(95%CI 0.732~0.815),敏感度为0.73(0.65~0.80),特异度为0.69(0.64~0.74)。校准曲线显示,非参数校准曲线大致沿45°理想校准曲线分布,模型平均校准误差为0.006。决策曲线分析显示,在0.10~0.55的阈值概率范围内模型临床净获益较高。 结论 本研究构建的预测模型具有良好的区分度与校准度,可用于早期识别重症卒中患者ENAD的高危人群,为临床实施预防策略提供参考。 Objective To analyze the risk factors for enteral nutrition-associated diarrhea (ENAD) in severe stroke patients, and to develop and validate a risk prediction model for ENAD. Methods Patients with severe stroke who received enteral nutrition and were admitted to the Emergency Department of Beijing Tiantan Hospital, Capital Medical University, between August 1, 2023, and November 30, 2025, were retrospectively and consecutively enrolled. They were randomly divided into a training set and a validation set in a 6∶4 ratio. The least absolute shrinkage and selection operator (LASSO) regression was employed to screen variables, followed by multivariate logistic regression to construct the prediction model. The AUC of the ROC curve, calibration curve, and decision curve analysis were used to evaluate the discrimination, calibration, and clinical net benefit of the model. Results A total of 1206 patients with severe stroke were included in this study, and the incidence of ENAD was 30.6% (369/1206). In the training set, a history of coronary artery disease (OR 2.22, 95%CI 1.26-3.92, P=0.006) and the use of laxatives (OR 2.35, 95%CI 1.58-3.48, P<0.001) were significantly associated with increased risk, whereas higher serum albumin levels were significantly associated with reduced risk (OR 0.34, 95%CI 0.23-0.52, P<0.001). The AUC of the model was 0.777 (95%CI 0.742-0.812) in the training set and 0.774 (95%CI 0.732-0.815) in the validation set, with sensitivities of 0.75 (0.70-0.81) and 0.73 (0.65-0.80) and specificities of 0.68 (0.63-0.72) and 0.69 (0.64-0.74), respectively. The calibration curve showed that the non-parametric calibration curve approximately followed the 45° ideal calibration line, with a mean calibration error of 0.006. Decision curve analysis showed that the model provided higher clinical net benefit within a threshold probability range of 0.10-0.55. Conclusions The prediction model developed in this study showed good discrimination and calibration and may be useful for the early identification of high-risk patients with ENAD among those with severe stroke, providing a reference for the clinical implementation of preventive strategies.

    2026
    引用
    AI阅读
    加入学术空间
    4烟雾病血管重构的研究进展Research Progress in Vascular Remodeling of Moyamoya Disease
    CHEN Haoyuan

    烟雾病是一种慢性进行性脑血管疾病,典型特征为双侧颈内动脉及其主要分支进行性狭窄、闭塞,同时颅底出现异常扩张的血管网。患者常以脑缺血或脑出血为首发症状,其大血管狭窄、闭塞及小血管代偿与患者临床表型和预后相关。血管重构在烟雾病的发生发展中具有重要作用,但具体机制尚不明确。越来越多的证据表明,遗传、免疫和炎症等因素参与烟雾病血管重构,目前已发现多种基因多态性和信号通路改变与烟雾病发病相关,其中环指蛋白213(RNF213)是东亚人群的主要易感基因;免疫因素亦为潜在诱发因素,烟雾病患者外周循环和颅内动脉中均发现存在免疫细胞浸润;此外,多种细胞因子已被证实可促进烟雾状血管生成。烟雾状血管的病理可见内膜纤维细胞增厚、内弹性膜破坏、中膜变薄和微小动脉瘤形成。DSA为诊断烟雾病的金标准。Suzuki分期、Matsushima分级及中国代偿评分可用于评估血管重构。目前尚无逆转烟雾病血管重构的药物,治疗主要通过卒中预防和脑血运重建术改善脑灌注。未来需借助动物模型、多组学和精准医学深化机制研究与治疗。 Moyamoya disease is a chronic progressive cerebrovascular disease characterized by progressive stenosis and occlusion of the bilateral internal carotid arteries and their main branches, accompanied by an abnormally dilated vascular network at the base of the brain. Patients often present initially with cerebral ischemia or cerebral hemorrhage. Large-vessel stenosis/occlusion and small-vessel compensation are associated with clinical phenotype and prognosis. Vascular remodeling plays an important role in the development and progression of moyamoya disease, but the precise mechanisms remain unclear. Increasing evidence indicates that genetic, immunological, and inflammatory factors are involved in the vascular remodeling of moyamoya disease. Multiple gene polymorphisms and signaling pathway alterations have been associated with the pathogenesis of moyamoya disease, and ring finger protein 213 (RNF213) has been identified as the major susceptibility gene in East Asian populations. Immunological factors are also potential triggers. Immune cell infiltration has been observed in both the peripheral circulation and intracranial arteries of patients with moyamoya disease. In addition, various cytokines have been shown to promote moyamoya vessel angiogenesis. Pathologically, moyamoya vessels show intimal fibrocellular thickening, disruption of the internal elastic membrane, medial thinning, and microaneurysm formation. DSA is the gold standard for diagnosing moyamoya disease. The Suzuki stage, Matsushima grading, and Chinese compensatory score can be used to assess vascular remodeling. Currently, no drug can reverse vascular remodeling in moyamoya disease; treatment mainly relies on stroke prevention and cerebral revascularization surgery to improve cerebral perfusion. Future studies should use animal models, multi-omics, and precision medicine to further elucidate the mechanisms and treatment of moyamoya disease.

    2026
    引用
    AI阅读
    加入学术空间
    5以反复缺血性卒中为表现的青年法布里病1例报道A Young Patient with Fabry Disease Presenting with Recurrent Ischemic Stroke: A Case Report
    CAO Zhentang

    法布里病是一种X连锁溶酶体贮积症,由α-半乳糖苷酶A基因突变引起α-半乳糖苷酶A活性缺乏或降低,导致三己糖酰基鞘脂醇及其衍生物在多脏器蓄积,进而引起多系统损害。该病临床表现高度异质,易漏诊和误诊。本文报道1例具有明确家族史的青年男性患者,自幼出现神经病理性疼痛,后以反复缺血性卒中及发作性头晕就诊。经α-半乳糖苷酶A活性和基因检测确诊为法布里病,并启动酶替代治疗。本文结合相关文献总结法布里病的神经系统表现,旨在提高神经科医师对该病的识别能力,促进早期诊断和规范治疗。 Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the α-galactosidase A gene, resulting in deficient or reduced α-galactosidase A activity. This enzymatic defect leads to the accumulation of globotriaosylceramide and its derivatives in multiple organs, causing multisystem damage. Owing to its marked clinical heterogeneity, Fabry disease is prone to misdiagnosis or delayed diagnosis. We report a young male patient with a positive family history who had childhood-onset neuropathic pain and later presented with recurrent ischemic stroke and paroxysmal dizziness. The diagnosis of Fabry disease was confirmed by α-galactosidase A activity assay and genetic testing, and enzyme replacement therapy was initiated. By reviewing the relevant literature, this report summarizes the neurological manifestations of Fabry disease, aiming to enhance neurologists’ awareness of the disease and facilitate early diagnosis and standardized treatment.

    2026
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 4557 篇论文

    高被引作者

    作者引用发文
    Wanliang Du450425
    Yongjun Wang3568280
    Min Zhao33643
    Xianwei Wang31447
    Zheng Li30755
    WenWen Qi30711
    Liao Xiaoling223619
    GuiHong Wang217018
    Haiqiang Qin214146
    Jing Jing207226

    高产作者

    作者引用发文
    Yongjun Wang3568280
    Xingquan Zhao1956218
    Yilong Wang1345148
    Chunxue Wang940146
    Liping Liu70389
    Zixiao Li45885
    ZhongHua Yang10779
    Haiqiang Qin214146
    Yingqi Xing50344
    Huaguang Zheng34944

    相关期刊

    Chinese Journal of Cerebrovascular Diseases
    Journal of Clinical Neurology
    Chinese Journal of Neuromedicine
    Neural Injury and Functional Reconstruction
    Chinese Journal of Neurology
    Chinese Journal of Neuroimmunology and Neurology
    Journal of Apoplexy and Nervous Diseases
    Stroke and Nervous Diseases
    International Journal of Geriatrics
    中华脑血管病杂志(电子版)